Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC Attack
2022-501438-46-00Phase 3Authorised
- Sponsor
- Johns Hopkins University
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in retinitis pigmentosa (RP) comparing N-acetylcysteine with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Planned start Apr 2023; status: authorised.
02
Drugs
acetylcysteine
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on 2022-501438-46-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501438-46-00.